The researchers have conducted a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique aimed at ...

CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...

Imagine developing a first-of-its-kind therapy that saved the life of one woman dying from colon cancer, only to lose the financial backing needed to bring it to market. That’s the reality for ...

CRISPR Therapeutics has revealed promising but early data from its first clinical study of a gene editing therapy to lower ...

In the ongoing effort to find better ways to fight cancer, scientists have developed a creative approach that uses the body’s ...

Developed at the Children's Hospital of Philadelphia (CHOP) and called Zynteglo, the medicine uses the patient's own stem ...

CRISPR Therapeutics, whose CEO is Samarth Kulkarni, and Vertex Pharmaceuticals earned the first U.S. Food and Drug ...

Nkure Therapeutics and Crispr Therapeutics partner to develop off-the-shelf CAR T therapy for oncology in India.

A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic ...